<div id="readability-page-1"><p>Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) shares traded up 9.9% during trading on Wednesday after Citizens Jmp upgraded the stock from a market perform rating to a market outperform rating. Citizens Jmp now has a $5.00 price target on the stock. Iovance Biotherapeutics traded as high as $4.13 and last traded at $4.11. 11,445,895 shares were traded  during mid-day trading, a decline of 18% from the average session volume of 13,949,900 shares. The stock had previously closed at $3.74.</p><ul><li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li></ul><p>Several other research analysts have also weighed in on IOVA. Barclays upped their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, February 25th. The Goldman Sachs Group  restated a &#34;sell&#34; rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a report on Thursday, February 5th. Wall Street Zen raised shares of Iovance Biotherapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday. Finally, Chardan Capital lowered their target price on Iovance Biotherapeutics from $17.00 to $16.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued  a Sell rating to the company. Based on data from MarketBeat.com, Iovance Biotherapeutics currently has an average rating of &#34;Hold&#34; and a consensus target price of $8.63.</p><p><b>Check Out Our Latest Analysis on IOVA</b></p><h2>Institutional Inflows and Outflows</h2><ul><li>The Top 5 Analysts Ranked by MarketBeat and Stocks They Cover</li></ul><p>Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of  Iovance Biotherapeutics by 161.2% in the first quarter. Royal Bank of Canada now owns 522,887 shares of the biotechnology company's stock worth $1,740,000 after acquiring an additional 322,680 shares during the last quarter.  AQR Capital Management LLC grew its position in  Iovance Biotherapeutics by 279.0% in the 1st quarter. AQR Capital Management LLC now owns 59,540 shares of the biotechnology company's stock worth $195,000 after purchasing an additional 43,829 shares during the last quarter.  Goldman Sachs Group Inc. raised its position in shares of  Iovance Biotherapeutics by 30.5% during the first quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company's stock valued at $18,554,000 after buying an additional 1,301,846 shares during the last quarter.  UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of  Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company's stock valued at $19,239,000 after buying an additional 3,869,617 shares during the period.  Finally, Envestnet Asset Management Inc. grew its position in  Iovance Biotherapeutics by 112.1% during the second quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company's stock worth $82,000 after buying an additional 25,083 shares in the last quarter. 77.03% of the stock is owned by institutional investors. </p><h2>Iovance Biotherapeutics Price Performance</h2><p>The business's 50 day simple moving average is $2.76 and its 200 day simple moving average is $2.45. The stock has a market cap of $1.70 billion, a P/E ratio of -3.69 and a beta of 0.69. </p><ul><li>How to Trade Stocks Online the Right Way </li></ul><p>Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative return on equity of 54.54% and a negative net margin of 148.41%.The business had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million.  Research analysts predict that  Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year. </p><h2>About Iovance Biotherapeutics</h2> (Get Free Report)<p>Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.  </p><p>Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Iovance Biotherapeutics</li><li>CSE: ALEN.U is targeting a fast-growing digital wellness market</li><li>New Copper-Rich “Kraken” Zone Discovered</li><li>America’s 1776 happening again</li><li>Elon did WHAT in 19 days?!</li><li>Silver's squeeze is tightening - opportunity forming</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Iovance Biotherapeutics Right Now?</h2><p>Before you consider Iovance Biotherapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iovance Biotherapeutics wasn't on the list.</p><p>While Iovance Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IOVA

SBIO

IBBQ

<p>Iovance Biotherapeutics (NASDAQ:IOVA) shares rose 9.9% following an upgrade from Citizens Jmp, which changed its rating from market perform to market outperform with a price target of $5.00. The stock traded at $4.11, down from a previous close of $3.74. Analysts have mixed ratings, with six recommending buy, four hold, and two sell. Institutional investors hold 77.03% of the stock, and the company reported a revenue of $86.77 million, exceeding estimates. Iovance specializes in TIL immunotherapies for solid tumors, with its lead product in late-stage development for melanoma.</p>

Market Beat

Iovance Biotherapeautics

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher  After Analyst Upgrade